文献速递临床试验与 GCP

头盔式持续气道正压通气与经鼻高流量氧疗在COVID-19中的实用随机临床试验

Helmet continuous positive airway pressure versus high-flow nasal cannula in COVID-19: a pragmatic randomised clinical trial (COVID HELMET).
PubMed 文献 · Trials · 2020-12-03

本研究计划在瑞典赫尔辛堡医院的中等水平COVID-19队列病房开展由研究者发起的实用随机试验,拟纳入120例患者,1:1随机分配至经鼻高流量氧疗(HFNC)或头盔式持续气道正压通气(CPAP),主要结局为28天内无呼吸机天数(VFD),采用Mann-Whitney U检验,计划2020年6月开始招募,2021年上半年完成。研究假设头盔CPAP相比HFNC可减少有创机械通气需求且不降低生存率。

要点

  • 头盔CPAP可提供更高PEEP,理论上可能减少插管需求,但缺乏与HFNC的直接比较证据。
  • 试验计划纳入120例COVID-19低氧血症患者,1:1随机至HFNC或头盔CPAP。
  • 主要结局为28天内无呼吸机天数,采用Mann-Whitney U检验,把握度90%,显著性水平0.05。

核心结论

  • 研究假设头盔CPAP相比HFNC可减少有创机械通气需求,且不降低生存率。

研究设计与样本

  • 研究者发起的实用随机对照试验,在瑞典赫尔辛堡医院中等水平COVID-19队列病房进行。
  • 计划样本量120例,1:1随机分配至HFNC或头盔CPAP。
  • 采用Mann-Whitney U检验,把握度90%,显著性水平0.05,主要结局为28天内无呼吸机天数。
  • 计划2020年6月开始招募,2021年上半年完成。

关键数值与推荐

  • 主要结局为28天内无呼吸机天数(VFD)。
  • 样本量120例,1:1随机,把握度90%,显著性水平0.05。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patients with COVID-19 and hypoxaemia despite conventional low-flow oxygen therapy are often treated with high-flow nasal cannula (HFNC) in line with international guidelines. Oxygen delivery by helmet continuous positive airway pressure (CPAP) is a feasible option that enables a higher positive end-expiratory pressure (PEEP) and may theoretically reduce the need for intubation compared to HFNC but direct comparative evidence is lacking. METHODS: We plan to perform an investigator-initiated, pragmatic, randomised trial at an intermediate-level COVID-19 cohort ward in Helsingborg Hospital, southern Sweden. We have estimated a required sample size of 120 patients randomised 1:1 to HFNC or Helmet CPAP to achieve 90% power to detect superiority at a 0.05 significance level regarding the primary outcome of ventilator free days (VFD) within 28 days using a Mann-Whitney U test. Patient recruitment is planned to being June 2020 and be completed in the first half of 2021. DISCUSSION: We hypothesise that the use of Helmet CPAP will reduce the need for invasive mechanical ventilation compared to the use of HFNC without having a negative effect on survival. This could have important implications during the current COVID-19 epidemic. TRIAL REGISTRATION: ClinicalTrials.gov NCT04395807 . Registered on 20 May 2020.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Tverring J, Åkesson A, Nielsen N, et al. Helmet continuous positive airway pressure versus high-flow nasal cannula in COVID-19: a pragmatic randomised clinical trial (COVID HELMET). Trials. 2020. PMID: 33272319. doi:10.1186/s13063-020-04863-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。